Investors Overview

Press Release

View printer-friendly version

BD Launches the BD FACSseq™ Cell Sorter with BD™ Precise Assays for High Precision Single Cell Genomics

Study to be Presented at the American Society of Human Genetics 2015 Annual Meeting Demonstrates Applications for High-Resolution Gene Expression Studies

BALTIMORE and SAN JOSE, Calif., Oct. 6, 2015 /PRNewswire/ -- BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today launched its first dedicated product specifically for single cell genomics applications with BD FACSseq, a high-throughput cell sorter designed for single cell genomic studies, combined with BD Precise Assays for single cell gene expression analysis. A poster demonstrating the performance of the BD FACSseq cell sorter and BD Precise Assays for targeted gene expression will be presented at the American Society of Human Genetics (ASHG) 2015 Annual Meeting. The BD FACSseq cell sorter and BD Precise Assays are currently for research use only.

Understanding the genomic differences of individual cell types provides unique insights into disease characteristics that have the potential to identify new approaches for developing targeted therapeutics. The BD FACSseq cell sorter combined with BD Precise Assays offers a high-throughput research method for single cell gene expression analysis to enable thousands of cells to be analyzed accurately, quickly, easily and affordably.

"Today, life science researchers require analysis of hundreds or thousands of single cells for single cell genomic studies," said Stephen Gunstream, vice president of global genomics at BD. "The BD FACSseq cell sorter and BD Precise Assays provide an end to end solution for single cell analysis that automates cell selection and isolation, streamlines targeted enrichment, eliminates the need for expensive consumables or equipment, and simplifies downstream analysis."

BD Precise Assays, a product line developed at Cellular Research, Inc. which was recently acquired by BD, allows for a high throughput single cell genetic analysis based on their proprietary Molecular Indexing technology to enable gene expression profiles from single cells. This technology, combined with BD's cell sorting capabilities, provides for a simple and integrated workflow for single cell analysis.

The BD FACSseq cell sorter and BD Precise Assays will be on display at the ASHG exhibit hall in booth 419. Meeting attendees are also invited to attend a breakfast workshop on Oct. 8 at 7:30 a.m. at the Baltimore Convention Center, in Rooms 349/350, Level 3. To learn more, visit http://www.bdbiosciences.com/go/facsseq.

The BD FACSseq cell sorter will be available through unrestricted release in early 2016 worldwide.

About BD

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.

Contacts:

Lindsay Roman
BD Public Relations
201.847.4312
Lindsay_Roman@bd.com

Monique N. Dolecki
BD Investor Relations
201.847.5378
Monique_dolecki@bd.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-launches-the-bd-facsseq-cell-sorter-with-bd-precise-assays-for-high-precision-single-cell-genomics-300154582.html

SOURCE BD (Becton, Dickinson and Company)

Investor Highlights

Placeholder

Meet Jonathan

Moments after crossing the finish line of a half marathon, Jonathan went into cardiac arrest due to a congenital defect in his artery.
Placeholder

Drone Delivery Capabilities

See how BD and WeRobotics worked to advance drones for healthcare in the Peruvian Amazon
Placeholder

AMR Leadership

BD solutions to combat antimicrobial resistance

© 2019 BD. All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.